Bicycle Therapeutics Plc - ADR
BCYC
Get informed when a big investor buys or sells
+ FollowMarket Cap$247.84M
Close$
$-2.25
163.5% downside
Current Fair Value
163.5% downsideOvervalued by 163.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $247.84 Million |
|---|---|
| Enterprise Value | $-245,652,785.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.16 |
| Beta | 1.68 |
| Outstanding Shares | 69,804,828 |
Return
| Return on Equity | -37.32% |
|---|---|
| Return on Assets | -31.39% |
| Return on Invested Capital | -37.98% |
Valuation & Multiples
| P/E Ratio | -1.3 |
|---|---|
| PEG | 3.59 |
| Price to Sales | - |
| Price to Book Ratio | 0.51 |
| Enterprise Value to Revenue | -4.01 |
| Enterprise Value to EBIT | 1.16 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$4.77 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$12.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 243.24% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 53.34% |
|---|---|
| Total Invested | $77,225▼ 99.95% |
| Investors Holding | 1▼ 111.00% |
ESG Score
No data
About Bicycle Therapeutics Plc
CEO: Kevin Lee